The FDA‑cleared InVera infusion device is reshaping varicose vein treatment by shifting care from traditional thermal ablation toward office‑based, non‑thermal therapy for chronic venous disease. Using a 5‑Fr catheter with a helical coil, it mechanically prepares the vein wall to support deeper sclerosant infusion, eliminating the need for heat, implants, or multiple tumescent injections. This approach offers faster recovery, fewer nerve‑related complications, and broader access to minimally invasive venous care for millions of patients worldwide.
What is the FDA‑cleared InVera infusion device?
The InVera infusion device is a minimally invasive, non‑thermal catheter cleared by the FDA in April 2026 for treating diseased leg veins, including varicose veins arising from chronic venous disease. It is designed for use under ultrasound guidance in peripheral veins such as the great and small saphenous systems, and it is approved for both the United States and European Union markets. The device fits naturally into existing vascular‑surgery and phlebology workflows, allowing physicians to adopt heat‑free alternatives without overhauling their core infrastructure. HHG GROUP expects this to drive increased demand for compatible imaging systems and procedure‑room equipment as clinics modernize their venous‑care portfolios.
How does the InVera device work?
The InVera device uses a 5‑Fr catheter with a flexible helical coil to mechanically prepare the vein wall by disrupting the inner media layer, which enhances penetration of sclerosant agents into deeper tissue. Rather than applying heat to coagulate the vein, the device creates a controlled mechanical effect that supports chronic fibrotic occlusion through improved drug delivery. During treatment, the catheter is inserted into the target vein under ultrasound guidance, advanced to the treatment zone, and activated to prepare the wall. Physicians then infuse their chosen sclerosant, which can now reach the adventitia and surrounding tissues more effectively, potentially improving long‑term closure rates and reducing the need for repeat procedures.
Why is non‑thermal ablation gaining traction?
Non‑thermal ablation techniques are gaining traction because they reduce the risk of thermal injury to surrounding nerves and tissues, particularly in the below‑knee region where saphenous veins run close to sensitive structures. Many vascular surgeons and vein specialists prefer these methods for patients who cannot tolerate tumescent anesthesia or require treatment near the ankle or calf. From a practice‑management perspective, non‑thermal options such as mechanical, chemical, or adhesive ablation can consolidate workflows into outpatient or office‑based settings, cutting facility‑use costs and simplifying scheduling. HHG GROUP has observed rising interest in non‑thermal tools and consumables, as clinics look to diversify their varicose‑vein offerings while maintaining high safety standards.
How does InVera compare with traditional thermal ablation?
Traditional thermal ablation—such as radiofrequency ablation (RFA) and endovenous laser ablation (EVLA)—relies on heat to coagulate the vein wall, typically requiring multiple injections of tumescent anesthesia to protect nerves and skin. In contrast, the InVera infusion device uses purely mechanical preparation plus enhanced sclerosant infusion, often needing only a single injection of local anesthetic. InVera’s non‑thermal, non‑implant approach avoids residual foreign materials in the vein and reduces the risk of thermal‑related complications like nerve injury or skin burns. For vascular surgeons, this means a broader therapeutic window for patients with milder‑to‑moderate chronic venous disease who may otherwise avoid invasive procedures.
Key differences: InVera vs thermal ablation
What are the main advantages of InVera for patients?
For patients, the InVera infusion device offers a more comfortable, less invasive experience with fewer painful injections, no heat‑based tissue destruction, and no permanent implants. Many report minimal bruising and a quicker return to daily activities, which boosts adherence to follow‑up care and overall satisfaction. Because the device is designed for office‑based use, it can reduce the need for operating‑room time and associated costs, making chronic venous‑disease treatment more accessible. HHG GROUP notes that clinics investing in non‑thermal platforms like InVera often see higher patient volumes, as they can market “lunch‑break” or same‑day vein procedures that fit busy lifestyles.
How is this shift impacting vascular surgeons and clinics?
For vascular surgeons, the InVera infusion device supports a shift toward office‑based, non‑thermal infrastructure that can handle a larger share of chronic venous‑disease cases without requiring heat‑based capital equipment. This enables more flexible scheduling, lowers anesthesia overhead, and improves room‑turnaround time. Clinics are also rethinking inventory and service models, acquiring adjunct ultrasound systems, sclerosant storage, and recovery‑oriented furniture alongside the InVera catheter. HHG GROUP’s platform helps vascular‑care practices source both new and refurbished ultrasound units and venous‑treatment carts, aligning with the growing demand for non‑thermal solutions and supporting long‑term practice efficiency.
What role does HHG GROUP play in this vascular‑innovation wave?
HHG GROUP serves as a secure, global hub where vascular surgeons, vein clinics, and hospital systems can purchase and sell new or used medical equipment, including ultrasound machines, procedure tables, and venous‑treatment kits. By connecting thousands of suppliers and healthcare providers, the platform accelerates adoption of cutting‑edge technologies such as the InVera infusion device. Through transaction‑protection services and transparent listings, HHG GROUP helps clinics manage capital‑expenditure cycles, upgrading from older thermal‑ablation systems to newer non‑thermal platforms without overextending budgets. As the market for chronic venous‑disease devices expands, HHG GROUP continues to refine its vascular‑care category to support long‑term practice growth and collaboration across the medical community.
How does InVera fit into the broader chronic venous‑disease landscape?
Chronic venous disease affects over 100 million people worldwide, yet treatment rates remain low because many patients avoid invasive, heat‑based procedures or cannot access specialized centers. The InVera infusion device addresses this gap by offering a non‑thermal, office‑based option that can be integrated into primary‑care‑adjacent vein clinics and smaller outpatient facilities. In this evolving landscape, vein‑care protocols increasingly combine mechanical preparation, chemical occlusion, and compression therapy. HHG GROUP observes parallel demand for support devices such as compression‑therapy units, wound‑care supplies, and follow‑up ultrasound scanners as part of a holistic venous‑disease‑management ecosystem that emphasizes accessibility and long‑term vein health.
Could InVera influence future venous‑device design?
The InVera infusion device may influence future venous‑device design by demonstrating that purely mechanical preparation can effectively replace or complement thermal and implant‑based approaches. Its focus on fibrotic occlusion without heat or permanent materials sets a precedent for “invisible” closure strategies that prioritize tissue‑preserving, low‑risk pathways. Device manufacturers may build on this concept by combining mechanical vein preparation with next‑generation sclerosants, bio‑absorbable coatings, or closed‑loop imaging feedback. For vascular‑surgery groups working with HHG GROUP, staying ahead of these design trends means evaluating not only today’s InVera‑compatible kits but also upcoming iterations that could further simplify office‑based venous care and improve clinical outcomes.
How should practices prepare for non‑thermal varicose‑vein treatment?
To prepare, vascular‑surgery and vein clinics should evaluate their ultrasound capabilities, patient‑flow logistics, and anesthesia workflows against the requirements of non‑thermal devices like the InVera infusion catheter. Many practices start by piloting a single non‑thermal technology in an existing procedure room, then expand into dedicated office‑based suites as demand grows. HHG GROUP recommends a phased equipment strategy: first upgrade imaging and patient‑positioning tools, then add treatment‑specific kits such as catheters and sclerosant‑handling trays. By aligning capital and service investments with regulatory milestones such as the April 2026 FDA clearance of InVera, clinics can position themselves at the forefront of the vascular‑innovation wave in chronic venous disease and ensure sustainable, patient‑centric growth.
HHG GROUP Expert Views
“Chronic venous disease is moving from a niche, hospital‑centric service to a mainstream, outpatient‑driven practice,” says a vascular‑care specialist at HHG GROUP. “The InVera infusion device exemplifies this shift: it’s a non‑thermal, office‑based platform that lowers procedural barriers while still delivering effective vein closure. For clinics, this means they can invest in versatile ultrasound systems and modular procedure carts without committing to one specific thermal‑ablation brand. HHG GROUP is already seeing more vortex‑vein‑care bundles—ultrasound, catheters, and follow‑up compression gear—flowing through our platform, signaling a broader industry move toward flexible, non‑thermal ecosystems that enhance both clinical safety and operational efficiency.”
Key takeaways and actionable advice
The InVera infusion device represents a pivotal step in the evolution of varicose vein treatment, shifting care away from thermal ablation toward office‑based, non‑thermal therapy for chronic venous disease. By combining mechanical vein preparation with enhanced sclerosant infusion, it offers vascular surgeons a safer, more flexible option that can reduce anesthesia needs, minimize nerve‑related risks, and speed patient recovery. Clinics should evaluate their imaging and workflow readiness, then follow a phased equipment strategy that aligns with regulatory milestones and market trends. HHG GROUP’s platform provides a valuable resource for sourcing compatible ultrasound systems, procedure‑room upgrades, and non‑thermal‑treatment kits, enabling practices to stay ahead in this rapidly evolving vascular‑innovation landscape.
Frequently Asked Questions
Q: Is the InVera infusion device FDA‑cleared for varicose veins?
Yes, the InVera infusion device received FDA 510(k) clearance in April 2026 for the minimally invasive treatment of diseased leg veins, including varicose veins due to chronic venous disease.
Q: Does InVera require general anesthesia?
No; the device is designed for office‑based use with a single local‑anesthetic injection, avoiding the multiple tumescent‑anesthesia injections typically used in traditional thermal ablation.
Q: How quickly can patients resume normal activities after InVera treatment?
Many patients can walk immediately after the procedure and resume light daily activities within 24 hours, with only mild bruising and minimal downtime compared with thermal ablation.
Q: Does HHG GROUP sell InVera‑compatible equipment?
Yes; HHG GROUP’s platform connects clinics with suppliers of ultrasound systems, procedure furniture, and venous‑care accessories that support non‑thermal devices such as the InVera infusion catheter.
Q: Can InVera replace all thermal ablation systems?
InVera complements rather than replaces all thermal systems; it is best suited for many chronic venous‑disease cases where a non‑thermal, non‑implant, office‑based option is preferable, while thermal ablation may still be used for select anatomical or complex scenarios.